Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137093 | 1.00 | MEN1 (0.47) | MEN1KMT2APTGS1MAPK1LTA4H | |
| SCHEMBL136888 | 0.89 | MAPK1 (0.57) | MEN1KMT2APTGS1MAPK1TSHR | |
| SCHEMBL17488469 | 0.81 | MEN1 (0.61) | MEN1KMT2APTGS1MAPK1TSHR | |
| SCHEMBL136543 | 0.80 | MEN1 (0.48) | MEN1KMT2APTGS1MAPK1LTA4H | |
| SCHEMBL102366 | 0.79 | PTGS1 (0.54) | PTGS1LTA4HTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL101661 | 0.79 | PTGS1 (0.49) | MEN1KMT2APTGS1LTA4HTSHR | |
| SCHEMBL102371 | 0.75 | MGLL (0.52) | PTGS1LTA4H | |
| SCHEMBL24596987 | 0.75 | CTSB (0.59) | MEN1KMT2ALMNA | |
| SCHEMBL14595222 | 0.75 | CTSB (0.59) | MEN1KMT2ALMNA | |
| SCHEMBL136889 | 0.75 | PTGS1 (0.50) | MEN1KMT2APTGS1MAPK1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752582-B2 | Augmenting moieties for anti-inflammatory compounds | LEHIGH UNIVERSITY (US) | 2020-08-25 | — | — | US | disclosed |
| US-20170044096-A1 | Augmenting Moieties for Anti-Inflammatory Compounds | LEHIGH UNIVERSITY | 2017-02-16 | — | — | US | disclosed |
| US-9512068-B2 | Augmenting moieties for anti-inflammatory compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160031804-A1 | Augmenting Moieties for Anti-Inflammatory Compounds | LEHIGH UNIVERSITY | 2016-02-04 | — | — | US | disclosed |
| US-8343971-B2 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | FAAH, FAAH2, TRPV1 | MEN1 2796/4885KMT2A 1600/4885PTGS1 74/4885 |
| US-10752582-B2 | Augmenting moieties for anti-inflammatory compounds | PTGES, PTGES3, LRBA | MEN1 4522/4885KMT2A 2466/4885PTGS1 11/4885 |
| US-20160031804-A1 | Augmenting Moieties for Anti-Inflammatory Compounds | PTGES, ICAM1, VCAM1 | MEN1 4476/4885KMT2A 2489/4885PTGS1 9/4885 |
| US-20170044096-A1 | Augmenting Moieties for Anti-Inflammatory Compounds | PTGES, PTGES3, LRBA | MEN1 4522/4885KMT2A 2466/4885PTGS1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.